TD Cowen reiterates Buy rating on Cerus stock, citing growth potential

Investing.com - TD Cowen has reiterated its Buy rating and $5.00 price target on Cerus (NASDAQ:CERS), highlighting the company’s undervalued growth opportunities. The stock, currently trading at $1.23, appears undervalued according to InvestingPro analysis, with analysts’ targets ranging from $4.00 to $5.00.

The research firm specifically pointed to the Intercept Fibrinogen Complex (IFC) product as a key emerging driver for Cerus’s future growth potential.

TD Cowen based its assessment partly on favorable feedback received from a high-volume trauma surgeon who has been using the IFC product since 2023.

The surgeon reported significant time and cost savings when using IFC compared to cryoprecipitate, along with other benefits not specified in the firm’s comments.

TD Cowen believes this surgeon’s positive experience represents what will soon become a larger trend in the medical community, potentially boosting adoption of Cerus’s IFC product.

In other recent news, Cerus Corporation reported its second-quarter 2025 earnings, revealing a revenue of $60.1 million, which surpassed the forecast of $54.37 million. The company also met earnings per share expectations at -$0.03. This strong performance was driven by growth in its platelets business and better-than-expected results from its newer Intercept Fibrinogen Complex (IFC) product line. Cantor Fitzgerald reiterated its Overweight rating and maintained a $4.00 price target for Cerus, noting that the company reported product revenue of $52.4 million, exceeding both their estimate of $49.5 million and the FactSet consensus of $48.0 million. This marks a year-over-year growth of approximately 16%, fueled by increased sales in IFC and global platelet products. Meanwhile, BTIG maintained its Neutral rating on Cerus, highlighting the stronger-than-anticipated performance in the quarter. These developments reflect the company’s continued expansion in its product offerings and market reach.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.